GlassScriptPhysician profile
Amber Gul
NPI 1043326978
$5,674.01
in general payments reported to CMS, 2019-2025
37 companies · $2,274 in 2025
The $2,274 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.82 · 2022: $588 · 2023: $1,386 · 2024: $1,327 · 2025: $2,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,987.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $873.00 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $795.45 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $684.98 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $402.48 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $328.51 | 2022-2025 | |
| Ardelyx, INC. | $237.00 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $232.74 | 2023-2025 | Rybelsus, Ozempic |
| Nestle Healthcare Nutrition INC. | $227.91 | 2022-2023 | |
| Gilead Sciences, INC. | $178.15 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.13 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $147.09 | 2022-2023 | Hetlioz |
| Amgen INC. | $142.14 | 2023-2025 | Otezla, Repatha, Repatha |
| Phathom Pharmaceuticals, INC. | $126.27 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $124.39 | 2022-2025 | Eliquis |
| Exact Sciences Corporation | $119.08 | 2023-2025 | Cologuard Collection Kit |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Gul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.